Psilocybin-facilitated Treatment for Chronic Pain

Eligibility Criteria

• 1. Female age 25-65;
• 2. Widespread musculoskeletal pain for ≥12 months;
• 3. Symptoms meeting the American College of Rheumatology (ACR) 2016 revisions to the 2010/2011 Fibromyalgia Diagnostic Criteria;
• 4. Participant completes daily report during baseline period (at least 80% completion rate);
• 5. Able to attend UAB for all scheduled appointments;
• 6. Ability to read/write in English;
• 7. No prior hallucinogen use or it will have been at least 3 years since last use of a hallucinogen;
• 8. Availability of a friend or family member into whose care the participant can be released (a key responsibility includes driving participants home) following their drug administration session;
• 9. A current average daily pain score of at least 5 on a 0-10 scale;
• 10. Discontinuation of exclusionary medication occurring at least two weeks and for at least 5 half-lives, whichever is longer, prior to drug administration day.
• 1. Males;
• 2. Use of opioid medications in the last 60 days;
• 3. Regular use of any anti-inflammatory medication (e.g., aspirin, ibuprofen, naproxen);
• 4. Use of blood thinning medication;
• 5. Use of tricyclic antidepressants, lithium, SSRIs, MAOIs, St. John's Wort, 5-hydroxytryptophan (5-HT), haloperidol, or other antipsychotic medications, mood stabilizers, or medications with serotonin activity;
• 6. Daily consumption of grapefruit juice;
• 7. Febrile illness or use of antibiotics in the 4 weeks before study commencement;
• 8. Planned surgery or procedures during the study period, or operated on in the 4 weeks prior to study commencement;
• 9. Planning to move from the Birmingham area in the next 6 months;
• 10. Planned vaccination during the study period, or vaccinated in the 4 weeks before study commencement;
• 11. Current participation in another treatment trial;
• 12. Pregnant or planning to become pregnant within 6 months, or currently breastfeeding;
• 13. Significant psychological comorbidity that in the discretion of the investigator compromises study integrity (i.e., presence of a current, clinically significant, untreated or unstable psychiatric condition) and/or a baseline HADS depression subscale score of ≥16;
• 14. Current or past history of any psychotic disorders;
• 15. Current or past history of bipolar I or II disorder;
• 16. First or second-degree relatives with any psychotic disorders, or bipolar I or II disorders;
• 17. Current suicidal or homicidal ideation (assessed using Columbia-Suicide Severity Rating Scale at each visit);
• 18. Diagnosed rheumatologic or auto-immune condition;
• 19. Blood or clotting disorder;
• 20. Current hypertension (exceeding 140 systolic or 90 diastolic at resting); resting heart rate\>90
• 21. Acute infection (oral temperature \>100°F);
• 22. High-sensitivity c-reactive protein (hs-CRP) ≥ 10mg/L;
• 23. Erythrocyte sedimentation rate (ESR) \> 60 mm/hr;
• 24. Positive rheumatoid factor;
• 25. Positive anti-nuclear antibody (ANA);
• 26. Levels of thyroid-stimulating hormone or free thyroxine outside UAB Hospital Labs reference values;
• 27. Use of UGT1A9, UGT1A10 and aldehyde or alcohol dehydrogenase enzyme inhibitors;
• 28. Dependent on any psychoactive drugs other than nicotine and caffeine;
• 29. Use of the antiviral drug efavirenz;
• 30. Use of PDE-5-Inhibitors, soluble guanylate cyclase (sGC) stimulators;
• 31. Severe anemia;
• 32. Phenylketonuria, chronic bronchitis, emphysema, asthma, diabetes, liver disease, and mucus with cough or slowed breathing
• 33. Use of any medication containing dextromethorphan (e.g., cough suppressants);
• 34. Pain due to other conditions or diseases that would complicate study participation or pain reporting.
• 35. Use of strong or moderate inhibitors of Cytochrome P450 2D6 (CYP2D6)
• 36. Poor metabolizers of CYP2D6 based on genotype